

Letter to the Editor: Brief Case Report

A “Trip” to the Intensive Care Unit: An Intravenous Injection of Psilocybin



INTRODUCTION

TO THE EDITOR: Psychoactive fungi, colloquially known as “magic mushrooms,” are known for their hallucinogenic properties mediated by psilocybin, a tryptamine-like alkaloid metabolized to the active constituent psilocin, a 5-HT_{2A} receptor agonist.¹ While usually taken orally, there are anecdotal reports on the Internet of the recreational injection of psilocybin, though the professional literature on this practice is scant.^{2,3} Here, we describe a case of a 30-year-old man who injected psilocybin intravenously resulting in an extended stay in the intensive care unit because of multiple-system organ failure.

Case

Mr. X was a 30-year-old man with bipolar disorder type I and a history of intravenous drug use admitted to the hospital after being brought to the emergency department by his family concerned that he was confused.

History gathered from his family was remarkable for recent non-adherence with his prescribed psychotropics (risperidone and valproate) and subsequent cycling between depressive

and manic states. He had reportedly been researching ways to self-treat his opioid dependence and depression.

In his reading, he encountered reports of therapeutic effects of microdosing lysergic acid diethylamide and hallucinogenic psilocybin mushrooms prompting him to inject what he had named “mushroom tea” – psilocybin mushrooms boiled down in water. He then “filtered” this substance by drawing it through a cotton swab before directly injecting the solution intravenously. Over the next several days, he developed lethargy, jaundice, diarrhea, nausea, and hematemesis before he was found by his family and taken to the emergency department.

Initial examination was remarkable for O₂ saturation on room air of 92%, heart rate of 100, and blood pressure of 75/47. He was noted to be ill-appearing with dry mucous membranes, mild cyanosis of the lips and nail beds, and jaundiced skin. His abdomen was diffusely tender to palpation without rebound or guarding. He was grossly confused and unable to meaningfully participate in an interview.

Laboratory studies revealed thrombocytopenia, hyponatremia, hyperkalemia, hypochloremia, hypocalcemia, acute renal insufficiency, and acute liver injury. Cardiac workup revealed elevated cardiac enzymes, and his electrocardiogram was remarkable for sinus tachycardia and early repolarization. He was then transferred to the intensive care unit for evidence of multiorgan failure, and he was started on intravenous fluids, multiple vasopressors, broad

spectrum antibiotics, and antifungal medications. His hospital course was further complicated by septic shock and acute respiratory failure requiring intubation on hospital day 2 and disseminated intravascular coagulation requiring plasmapheresis. Cultures confirmed both bacterial (ultimately cultured as *Brevibacillus*) and fungal (ultimately cultured and DNA identified by a specialist laboratory as *Psilocybe cubensis* – i.e., the species of mushroom he had injected was now growing from his blood) infections. He was treated for a total of 22 days in the hospital with 8 of them in the intensive care unit. At the time of writing, he is currently still being treated with a long-term regimen of daptomycin, meropenem, and voriconazole.

DISCUSSION

While it is evident that he was harmed through his use of psilocybin, current investigations of its therapeutic potential as an adjunct to psychotherapy in treating a variety of psychiatric conditions – including obsessive compulsive disorder, substance abuse disorder, anxiety, and depression – have been documented.^{4,5} The case reported previously underscores the need for ongoing public education regarding the dangers attendant to the use of this, and other drugs, in ways other than they are prescribed. It is unclear whether infection with a psychoactive fungus such as *P. cubensis* may prompt persistent psychoactive effects as seen with ingestion of the same species which could further

contribute to changes in perception and cognition.

Nicholas B. Giancola, B.A.
Clayton J. Korson, B.S.
Creighton University School of
Medicine, Phoenix, AZ
Jason P. Caplan, M.D.*

Curtis A. McKnight, M.D.
Department of Psychiatry,
Creighton University School of
Medicine, Phoenix, AZ

*Send correspondence and reprint
requests to Jason P. Caplan, MD,

Department of Psychiatry,
Creighton University School of
Medicine, 350 W. Thomas Road,
Phoenix, AZ 85013; e-mail: [jason.
caplan@chw.edu](mailto:jason.caplan@chw.edu)

References

1. Tylš F, Páleníček T, Horáček J: Psilocybin – summary of knowledge and new perspectives. *Eur Neuro-psychopharmacol* 2014; 24:342–356
2. van Amsterdam J, Opperhuizen A, van den Brink W: Harm potential of magic mushroom use: a review. *Regul Toxicol Pharmacol* 2011; 59:423–429
3. Curry SC, Rose MC: Intravenous mushroom poisoning. *Ann Emerg Med* 1985; 14:900–902
4. Johnson MW, Griffiths RR: Potential therapeutic effects of psilocybin. *Neurotherapeutics* 2017; 14:734–740
5. Carhart-Harris R, Leech R, Williams T, et al: Implications for psychedelic-assisted psychotherapy: functional magnetic resonance imaging study with psilocybin. *Br J Psychiatry* 2012; 200:238–244